Baird Medical announced the installation of its microwave ablation (MWA) system at Bakersfield Memorial Hospital in California, with the first procedure performed on February 11, 2026 by Endocrine Surgeon Dr. Tim Beck. The deployment marks the first use of the technology for benign thyroid nodules in the San Joaquin Valley.
The installation follows Baird Medical’s November 2023 FDA 510(k) clearance of its MWA platform and disposable needles, clearing the path for U.S. commercialization. By adding a U.S. hospital network to its customer base, the company gains a new revenue stream and demonstrates the commercial viability of its technology outside China.
Baird Medical’s 2024 financial results showed revenue of $37.04 million, up 17.7 % from $31.46 million in 2023, and earnings of $12.45 million, an 18.1 % increase. However, the company’s trailing‑12‑month earnings through June 30 2025 are reported as a loss of $3.2 million, indicating a sharp reversal in profitability that investors are monitoring closely.
The company’s strategy emphasizes expanding U.S. market penetration through clinical education and partnerships with leading medical centers. The Bakersfield deployment is the first U.S. customer win in the region and signals that Baird Medical is executing its international expansion roadmap, potentially improving long‑term growth prospects.
In the competitive U.S. thyroid ablation market, Baird Medical faces established players such as Medtronic and Boston Scientific. The company’s entry into the U.S. market positions it to capture a share of the growing minimally invasive treatment segment, but it must navigate pricing pressure and the need to demonstrate clinical outcomes to secure broader adoption.
While the article does not report a market reaction, the deployment is expected to be viewed positively by investors seeking evidence of U.S. traction, though the recent earnings reversal may temper enthusiasm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.